Precipio reports preliminary 2021 revenue of $8.9M, up 45% YoY; Q4 revenue $2.4M up 25%

Precipio, Inc.

2021-FY EPS reported -$0.40 revenue$8,849,000

Preliminary unaudited 2021 revenue $8.9M, up $2.8M (45%) from 2020.
Q4-2021 revenue $2.4M, a 25% increase from $1.9M in Q4-2020.
HemeScreen product Q4-2021 revenue $0.4M vs <$0.1M full-year 2020; annualized contracts now >$1.6M.
2022 outlook projects meaningful growth in pathology and HemeScreen, aiming to materially reduce cash burn.
New panels (CLL, BCR-ABL) expected in 2022 to drive revenue per customer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.